Wellcome TDF: Development of a novel, potent, allosteric EAAT1 inhibitor derived from an in-house hit compound for the treatment of T-cell Acute Lymphoblastic Leukaemia

Project Details

Short titleWellcome TDF: Development of a novel, potent, allosteric EAAT1 inhibitor derived from an in-house hit compound for the treatment of T-cell Acute Lymphoblastic Leukaemia
StatusFinished
Effective start/end date1/04/23 → 13/04/24

Funding

  • THE WELLCOME TRUST